uniQure N.V. - Ordinary Shares (QURE) Covered Calls

uniQure NV is engaged in the field of gene therapy and has developed a gene therapy product to receive regulatory approval in the European Union.

You can sell covered calls on uniQure N.V. - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for QURE (prices last updated Thu 4:16 PM ET):

uniQure N.V. - Ordinary Shares (QURE) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
9.75 -0.87 9.45 10.63 1.6M - 0.5
Covered Calls For uniQure N.V. - Ordinary Shares (QURE)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Apr 17 10 0.00 10.63 -5.9% -143.6%
May 16 10 1.05 9.58 4.4% 36.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

uniQure NV engages in the discovery, development, and commercialization of gene therapies. Its core gene therapies include AMT-060 for the treatment of hemophilia B; preclinical S100A1 therapeutic for the treatment of congestive heart failure; and Glybera a gene therapy that is designed to restore the LPL enzyme activity required to enable the processing, or clearance, of fat-carrying chylomicron particles formed in the intestine after a fat-containing meal. uniQure was founded on January 9, 2012 and is headquartered in Amsterdam, Netherlands.